Compare General Mills, Inc. (GIS) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
General Mills, Inc. vs Kymera Therapeutics Inc. Common Stock — how do they compare? General Mills, Inc. trades at $32.25 (market cap $17.02B), while Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B). The key difference: General Mills, Inc. is the larger of the two by market cap, and General Mills, Inc. pays a 7.67% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold General Mills, Inc. for 107 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| GIS | KYMR | |
|---|---|---|
Market Cap | $17.02B | $8.87B |
Volume | 7,979,067 | 779,107 |
Sector | Consumer Staples | Health |
52-Week High | $49.18 | $127.31 |
52-Week Low | $31.67 | $55.80 |
Typical Hold Time | 107 Days | 0 Days |
Enterprise Value | $30.20B | $8.26B |
Dividend Yield | 7.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
General Mills (GIS) trades at $32.11, down 1.8% on the day, reflecting recent pressure from a Q4 2025 earnings miss and a projected net loss for 2026. The stock shows a bearish technical trend, with key support at $32. Despite a low P/E of 9.23, profitability metrics like a negative ROE of -10.55% and a forecasted negative net income margin for 2026 highlight significant challenges. Recent news includes a CEO transition and a reaffirmed $0.61 quarterly dividend, but investor sentiment remains cautious amid declining revenues and margin pressures.
The outlook for GIS is clouded by execution risks in its turnaround strategy and macroeconomic headwinds. The high dividend yield offers income appeal, but the potential for a dividend cut and sustained earnings weakness presents substantial risk. Analyst consensus is predominantly Hold, with a $36 price target suggesting limited near-term upside, making the stock a speculative hold for income-focused investors tolerant of high risk.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About General Mills, Inc.
General Mills is a leading global packaged food company that produces snacks, cereal, convenient meals, yogurt, dough, baking mixes and ingredients, pet food, and superpremium ice cream. Its largest brands are Nature Valley, Cheerios, Old El Paso, Yoplait, Pillsbury, Betty Crocker, BLUE, and Haagen-Dazs. In fiscal 2022, 77% of its revenue was derived from the United States, although the company also operates in Canada, Europe, Australia, Asia, and Latin America. While most of General Mills' products are sold through retail stores to consumers, the company also sells products into the food-service channel and the commercial baking industry.
Read more on GIS →About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →
